CytomX Therapeutics, Inc.
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
Last updated:
Abstract:
The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to epidermal growth factor receptor (EGFR), and to methods of making and using these anti-EGFR activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
Status:
Grant
Type:
Utility
Filling date:
19 Jan 2018
Issue date:
14 Jul 2020